Jan 29 (Reuters) - The U.S. government said on Wednesday

it will consider opportunities to "bring greater transparency"

for the Medicare drug price negotiation program under President

Donald Trump's administration.

The price negotiation process was established under former

President Joe Biden's signature Inflation Reduction Act in 2022.

Earlier this month, the outgoing administration released a list

of 15 drugs that are set to undergo the process.

The drugs, which include Novo Nordisk's

blockbuster diabetes and weight-loss treatments Ozempic and

Wegovy, are among the most expensive for Medicare insurance

plans for people aged 65 and older or with disabilities.

The Centers for Medicare and Medicaid Services said it will

give opportunities for "stakeholders to provide specific ideas"

that can help improve the negotiation process. The agency

oversees the Medicare health program.